Here we show, that parallel resistance mechanisms appear during erlotinib-resistance development in-mutated NSCLC cells and highlight a role forexpression changes as an early response to erlotinib as well as a bypass-signaling mechanism.doi:10.1038/oncsis.2017.17K R Jakobsen...
因此,研究肺癌耐药机制,寻找克服策略,或者发展新的免疫治疗手段均具有重要的临床意义。 3、第一代egfr-tki[如吉非替尼(gefitinib)和厄洛替尼(erlotinib)]是标志着nsclc靶向治疗史上的重大事件。它预示着肿瘤靶向精准治疗的问世,并被证明是对具有egfr敏感突变的nsclc患者有效的一种可逆抑制剂,可以有效延长患者的生存期...
本发明涉及细胞生物学,尤其涉及一种耐阿美替尼的非小细胞肺癌细胞株hcc827/ar及其应用。 背景技术: 1、肺癌是目前全球发病率和死亡率最高的恶性肿瘤,可分为小细胞肺(sclc)和非小细胞肺癌(nsclc),非小细胞肺癌是肺癌最常见的类型,约占肺癌的85%-90%,一般发现时多为中晚期。非小细胞肺癌目前的主要治疗手段包括...
1. NSCLC细胞株EGFR突变状态和PD-L1表达的相关性分析提取NSCLC细胞株的总DNA并用PNA-LNA PCR检测EGFR突变状态。流式细胞分析检测NSCLC细胞株的PD-L1表达水平。在NSCLC细胞株的培养环境中加入人源性重组EGF并用流式细胞分析和实时定量PCR检测其PD-L1的表达。 2. EGFR-TKIs对EGFR-TKI敏感型和获得性耐药型NSCLC细胞...
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of treatment with EGFR-inhibitors, such as erlotinib. Multiple resista... Dianna,Hussmann,Anne,....
The majority of patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations inevitably progress in stage despite an initial substantial and rapid response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Previous research indicates that hypoxia may...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used to treat non-small cell lung carcinoma (NSCLC) patients that have EGFR-activating mutations. EGFR-TKI monotherapy in most NSCLC patients with EGFR mutations who initially respond to EGFR-TKIs results in ...
nsclc的突变体细胞对egfr表现hcc827xxxxx(dele746_a750) h3255( l858r ) 翻译结果5复制译文编辑译文朗读译文返回顶部 EGFR突变体NSCLC细胞系HCC827 (del e746_A750) H3255 (L858R) 相关内容 aIt will be a center of attraction, a place to live, work, learn and play.What will make it so important for...
HCC827EGFRcell growthNon-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and is characterized by more insensitivity to chemotherapy and poor prognosis. Epidermal growth factor receptor (EGFR) has been confirmed as a tumorigenic driving factor of NSCLC. Taspine has been ...
结论:全外显子测序检测TKI erlotinib浓度递增的方法诱导并筛选的TKI耐药细胞HCC827/ER中Spred3c.120delG突变发生频率100%,Spred3m RNA及蛋白几乎不表达;通过基因组中Spred3突变,使得蛋白失活而致Ras/Raf/MAPK信号通路活化而诱导HCC827/ER对TKI Erlotinib的耐药,可能是EGFR活化突变的NSCLC细胞HCC827经诱导产生获得性...